You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

13 search results for: prevalence

<b>Prevalence</b> of Food Allergy and Other Atopic Comorbidities in Children With AD

expert video

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

3 min

Dermatology

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the prevalence of food sensitization and food allergy in pediatric patients with AD, clarifying the difference between the two. Dr Boguniewicz also discusses the prevalence of other atopic comorbidities in children with AD

The <b>Prevalence</b> and Burden of Type 2 Inflammation in Patients With CRSwNP

expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

8 min

Rhinology

Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD.

expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

8 min

Pulmonology

Dr. Stephanie Christenson shares an overview of inflammatory pathways underlying COPD, including type 2 inflammation.

expert video

ERS 2023 | Contextualizing Clinical Presentation of COPD Through Disease Pathology

9 min

Pulmonology

Prof. Klaus Rabe shares an overview of the underlying pathology of COPD and the clinical consequences of pathologic changes.

expert video

The Burden of Atopic Dermatitis in Children – Bullying in School

1 min

Dermatology

Dr. Mark Koh talks about the prevalence of bullying of children with AD.

expert video

IMPACTO DE LOS SIGNOS Y SÍNTOMAS DE LA DERMATITIS ATOPICA EN LA CALIDAD DE VIDA: PRURITO, SUEÑO Y LESIONES

11 min

Dermatology

Debate sobre como impacta las lesiones, el picor y la falta de sueño sobre la calidad de vida del paciente con DA.

expert video

La DA en pacientes pediátricos: Entendiendo la Dermatitis Atópica en la población infantil

12 min

Dermatology

En esta tercera escala de ADVENT ON TOUR en MADRID contamos con la Dra. Sara Palencia, dermatóloga en el Hospital Universitario 12 de Octubre, que nos habla sobre la dermatitis atópica en la población infantil.

expert video

La DA en pacientes pediátricos: Debate y Discusión

16 min

Dermatology

La DA en pacientes pediátricos: Debate y Discusión.

expert video

Fisiopatología del prurigo nodular y carga de la enfermedad

11 min

Dermatology

Fisiopatología del prurigo nodular.

expert video

Shared and Unique Characteristics of AD, PN, and CSU

17 min

Dermatology

Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min

Dermatology

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SpainChange country/region